

# Key Information Document

**Purpose:** This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

## Product

**Janus Henderson Horizon Biotechnology Fund IU2 USD** ISIN: LU1897414568

A sub-fund of Janus Henderson Horizon Fund, a Luxembourg SICAV manufactured by **Janus Henderson Investors Europe S.A.**, a subsidiary of Janus Henderson Group plc. This Fund is authorised in Luxembourg and regulated by the Commission de Surveillance du Secteur Financier ("CSSF"). The Manager is authorised in Luxembourg and regulated by the CSSF, and relies on passporting rights under the UCITS Directive to manage the Fund on a cross-border basis and to market the Fund within the European Union. More information is available at [www.janushenderson.com](http://www.janushenderson.com) or by calling +352 26 19 21 24. This document is dated 8 December 2023.

## What is this product?

### Type

Janus Henderson Horizon Biotechnology Fund is a sub-fund of Janus Henderson Horizon Fund, an open-ended investment company organised under the laws of the Grand Duchy of Luxembourg. Janus Henderson Horizon Fund qualifies as an undertaking for collective investment in transferable securities (UCITS).

### Term

This investment has no maturity date. The Manufacturer has the right to terminate the product in a limited number of circumstances, as set out in the Prospectus.

### Objectives

The Fund aims to provide capital growth over the long term. Performance target: To outperform the NASDAQ Biotechnology Total Return Index by 2% per annum, before the deduction of charges, over any 5 year period. The Fund invests at least 80% of its assets in shares (equities) and equity-related securities of companies, which are biotechnology or biotechnology-related, of any size, including smaller capitalisation companies, in any country. The Fund may also invest in other assets including bonds (including convertible bonds), preference shares, cash and money

market instruments. The investment manager may use derivatives (complex financial instruments) with the aim of making investment gains in line with the Fund's objective, to reduce risk or to manage the Fund more efficiently. The Fund is actively managed with reference to the NASDAQ Biotechnology Total Return Index, which is broadly representative of the companies in which it may invest, as this forms the basis of the Fund's performance target and the level above which performance fees may be charged (if applicable). The investment manager has discretion to choose investments for the Fund with weightings different to the index or not in the index, but at times the Fund may hold investments similar to the index. This share class accumulates income which is retained within the price of the share class. You can buy, sell or switch shares in the Fund on any dealing day, as defined in the Fund's Prospectus. The Fund's Depositary is BNP Paribas, Luxembourg Branch.

### Intended Retail Investor

This Fund may not be appropriate for investors who plan to withdraw their money within 5 years. This Fund is designed to be used only as one component in several in a diversified investment portfolio. Investors should consider carefully the proportion of their portfolio invested into this Fund.

## What are the risks and what could I get in return?

### Risk Indicator

Lower Risk 1 2 3 4 5 6 7 Higher Risk

The risk indicator assumes that you keep the product for 5 years. The actual risk can vary significantly if you cash in at an early stage and you may get back less.

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

We have classified this product as 5 out of 7, which is a medium-high risk class.

This rates the potential losses from future performance at a

medium-high level, and poor market conditions will likely impact the capacity of the PRIIPs manufacturer to pay you.

**If the product currency differs from your home currency, the following applies: Be aware of currency risk. You will receive payments in a different currency, so the final return you will get depends on the exchange rate between the two currencies. This risk is not considered in the indicator shown above.**

This product does not include any protection from future market performance so you could lose some or all of your investment.

If we are not able to pay you what is owed, you could lose your entire investment.

Details of all relevant risks can be found in the Fund's prospectus, available at [www.janushenderson.com](http://www.janushenderson.com)

## Performance Scenarios

What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the product and a suitable benchmark over the last 10 years. Markets could develop very differently in the future.

**Recommended holding period: 5 years**

**Example Investment: USD 10,000**

Scenarios		If you exit after 1 year	If you exit after 5 years
Minimum	<b>There is no minimum guaranteed return. You could lose some or all of your investment.</b>		
Stress	<b>What you might get back after costs</b>	2,850 USD	1,750 USD
	Average return each year	-71.52%	-29.40%
Unfavourable	<b>What you might get back after costs</b>	6,470 USD	9,320 USD
	Average return each year	-35.27%	-1.41%
Moderate	<b>What you might get back after costs</b>	10,590 USD	15,520 USD
	Average return each year	5.93%	9.19%
Favourable	<b>What you might get back after costs</b>	17,040 USD	24,250 USD
	Average return each year	70.36%	19.39%

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

The stress scenario shows what you might get back in extreme market circumstances.

The unfavourable scenario occurred for an investment between August 2021 and September 2023.

The moderate scenario occurred for an investment in the benchmark between February 2017 and February 2022.

The favourable scenario occurred for an investment in the benchmark between February 2016 and February 2021.

## What happens if Janus Henderson Investors Europe S.A. is unable to pay out?

You may face a financial loss should the Manufacturer or Depository, BNP Paribas, Luxembourg Branch, default on their obligations. There is no compensation or guarantee scheme in place which may offset, all or any of, this loss.

## What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

### Costs over time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product and how well the product does. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed:

- In the first year, you would get back the amount that you invested (0 % annual return). For the other holding periods we have assumed the product performs as shown in the moderate scenario.
- USD 10,000 is invested.

	If you exit after 1 year	If you exit after 5 years
Total costs	777 USD	3,205 USD
Annual cost impact (*)	7.8%	4.2% each year

(\*) This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 13.4% before costs and 9.2% after costs.

We may share part of the costs with the person selling you the product to cover the services they provide to you. They will inform you of the amount.

## Composition of costs

One-off costs upon entry or exit		If you exit after 1 year
Entry costs	5.00% is the maximum amount you pay when entering this investment and you could pay less. If you invest through a third-party the person selling you the product will inform you of the actual charge.	Up to 500 USD
Exit costs	A charge of up to 1.00% may apply where the Manager suspects excessive trading by an investor (and specifically on subscriptions held for less than 90 days).	0 USD
Ongoing costs [taken each year]		
Management fees and other administrative or operating costs	1.00% is the estimated cost of managing, administering and operating the Fund.	100 USD
Transaction costs	0.62% is an estimate of the costs incurred when we buy and sell the underlying investments for the Fund. The actual amount will vary depending on how much we buy and sell.	62 USD
Incidental costs taken under specific conditions		
Performance fees	This is the impact of the performance fee. From your investment we take 20% of any returns that, subject to a High Water Mark, the Fund achieves above the NASDAQ Biotechnology Total Return Index.	115 USD

## How long should I hold it and can I take money out early?

### Recommended holding period: 5 years

This Fund should be considered a medium to long term investment. This means 5 years or more. The Fund's risk may vary if you cash in at an early stage. Fees may be applicable for exiting during the term of the Fund. Please refer to the 'Composition of Costs' table for details of applicable fees. You can sell your shares in the Fund on any Dealing Day as defined in the Prospectus, by using one of the methods described in the Prospectus.

## How can I complain?

Should you wish to complain you can do so by contacting us by email or post. Email: [JHIESAComplaints@janushenderson.com](mailto:JHIESAComplaints@janushenderson.com). Post: Janus Henderson Investors Europe S.A., Attn: Complaints handling officer, 2, Rue de Bitbourg, L-1273 Luxembourg. The complaints handling policy is available on the website, [www.janushenderson.com](http://www.janushenderson.com).

## Other relevant information

To obtain the Fund's Prospectus or the annual/semi-annual reports, which are published and made available to investors by law, or for the last published price of shares in the Fund or any additional information on the Fund, please visit [www.janushenderson.com](http://www.janushenderson.com). Documents are available free of charge in English and certain other languages. You may also contact the registered office of the Fund at 2, Rue de Bitbourg, L-1273 Luxembourg, or your local representative office. Past performance scenarios and 4 years of past performance data can be found on our website at [www.janushenderson.com](http://www.janushenderson.com).

The Representative in Switzerland is First Independent Fund Services Ltd., Feldeggstrasse 12, 8008 Zurich, Switzerland. The Paying Agent in Switzerland is Banque Cantonale de Genève, 17, quai de l'Île, CH-1204 Geneva, Switzerland. The Prospectus, the key information documents, the Articles of Incorporation of the Company as well as the annual and semi-annual reports may be obtained free of charge from the Representative in Switzerland.